Harshvardhan Iyer

Dr. Harshvardhan Iyer

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Global Spine Journal
Verified
Journal Article
Open access
Enrique González GallardoEnrique González Gallardo
Enrique González Gallardo
JEJustyna O. Ekert
Justyna O. Ekert
HIHarshvardhan Iyer
Harshvardhan Iyer
JLJuan Pablo Navarro-García de Llano
Juan Pablo Navarro-García de Llano
JSJesús E. Sánchez-Garavito
Jesús E. Sánchez-Garavito
RNRodrigo Navarro-Ramírez
Rodrigo Navarro-Ramírez
Study Design: Systematic Review. Objective: To assess the current literature regarding the accuracy of different imaging modalities and criteria used to assess lumbar fusion, and their correlation with surgical direct observation as the current Gold Standard. Methods: Following PRISMA guidelines, we conducted a comprehensive search of PubMed, Embase, Google Scholar, and Cochrane Library, studies were included if they focused on patients with a prior history of lumbar interbody fusion and at least 1 year of radiographic follow-up. The review assessed the sensitivity, specificity, and accuracy of different imaging techniques, and their correlation with surgical findings. Results: Thirteen studies (1989-2019) were reviewed, including 715 patients, common imaging modalities included plain radiographs (53.8%), Computed Tomography (CT) (69.2%), and dynamic radiographs (30.7%). CT appeared as the most utilized modality post-2006. There was substantial variability in diagnostic accuracy, with CT showing high variability in sensitivity and specificity. Descriptive criteria for fusion were widely used, but interobserver agreement was generally low. Conclusion: The review highlights a lack of standardized criteria for assessing lumbar fusion. Despite advancements in imaging techniques, the variability in diagnostic parameters suggests a need for consensus and multicentric studies to stablish reliable, universal criteria for evaluating fusion success.

30 July 2024 in World Neurosurgery
Verified
Journal Article
Closed access
JSJesus E. Sanchez-Garavito
Jesus E. Sanchez-Garavito
CPCarlos Perez-Vega
Carlos Perez-Vega
HIHarshvardhan Iyer
Harshvardhan Iyer
JZJorge Rios Zermeno
Jorge Rios Zermeno
GMGuiselle Navarro Martinez
Guiselle Navarro Martinez
SSSusan L. Samson
Susan L. Samson

27 September 2024 in Operative Neurosurgery
Verified
Journal Article
Closed access
JLJuan P. Navarro-Garcia de Llano
Juan P. Navarro-Garcia de Llano
MCMacarena Fuentes-Fernandez Cueto
Macarena Fuentes-Fernandez Cueto
ARAndrew P. Roberts
Andrew P. Roberts
JSJesus E. Sanchez-Garavito
Jesus E. Sanchez-Garavito
SSSiddharth Shah
Siddharth Shah
KAKingsley O. Abode-Iyamah
Kingsley O. Abode-Iyamah
BACKGROUND AND OBJECTIVES: Awake minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) generates minimal surrounding tissue damage and has been shown to be a safe, time-effective, and cost-reductive technique in single-level procedures. The purpose of this study was to advocate for the utilization of multilevel MIS-TLIF even in challenging cases as it has demonstrated positive outcomes. METHODS: Chart review was conducted for consecutive patients undergoing awake multilevel MIS-TLIF from 2020 to 2023. Various demographic, preoperative, and postoperative variables were collected and descriptively analyzed. RESULTS: Sixteen patients underwent multilevel awake MIS-TLIF at our institution during the specified period. Among them, 87.5% underwent a two-level procedure and 12.5% a three-level procedure. The median age ± IQR was 69.5 ± 11 years, with a slight male predominance (56.25%). Common comorbidities included hypertension (56.25%), obesity (37.5%), sleep apnea (25%), and type 2 diabetes (18.75%). The American Society of Anesthesiologists risk was 2 in 43.75% of patients and 3 in 56.25%. All patients presented pain, and 12.5% showed motor deficit. Intraoperative data showed a median of 196 minutes in the operating room where 156 ± 27.75 minutes corresponded to actual procedure time. The median estimated blood loss was 50 ± 70 cc. In the immediate postoperative period, 1 patient had nausea and emesis, and 1 reported fatigue. The median pain score during this period was 4.6 ± 2.03. Pain control medications were required for various patients, with methocarbamol (50%), hydromorphone (37.5%), and oxycodone (25%) being the most commonly prescribed in the postanesthesia care unit. No patient had new neurological deficits after the surgical intervention. The median length of stay was 2 days ±1.25. All patients were discharged with no complications. CONCLUSION: Multilevel awake MIS-TLIF emerges as a safe and effective technique for complex cases, enhancing patient quality of life with minimal blood loss and postoperative pain.

13 May 2025 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
HIHarshvardhan Iyer
Harshvardhan Iyer
OAOgechukwu K. Ariwodo
Ogechukwu K. Ariwodo
CMChase Mckevitt
Chase Mckevitt
PMPaola Suarez Meade
Paola Suarez Meade
LMLina Marenco-Hillembrand
Lina Marenco-Hillembrand
KCKaisorn L. Chaichana
Kaisorn L. Chaichana

30 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
HIHarshvardhan Iyer
Harshvardhan Iyer
HHHarry Hoffman
Harry Hoffman
MSMahesh Seetharam
Mahesh Seetharam
SASteven Attia
Steven Attia
OAOluwaseun O. Akinduro
Oluwaseun O. Akinduro
Background/Objectives: Chordoma, a rare slow-growing malignant bone tumor, remains therapeutically challenging due to its invasive nature. We examined institutional outcomes comparing imatinib and brachyury-directed vaccines. Methods: We used data from three sites of our quaternary care academic institution to analyze demographics, time to progression, overall survival, and adverse events in chordoma patients treated with imatinib or enrolled in a brachyury vaccine trial. Results: We included a total of 52 patients (8 in the brachyury vaccine cohort and 44 in the imatinib cohort) in the analysis. As expected, sacrococcygeal location was the most predominant in both cohorts: 62.5% in the brachyury cohort and 45.5% in the imatinib cohort. No demographic differences were present between the cohorts. ECOG was similar in both groups (p = 0.796). The primary outcome, time to progression (TTP), was shorter in the brachyury compared to the imatinib cohort (5.6 vs. 13 months, p = 0.0589), almost reaching statistical significance. Overall survival (OS) was comparable, 211 vs. 212 months for the brachyury and imatinib cohorts, respectively (p = 0.277). Although the brachyury vaccine cohort presented a higher incidence of adverse events than the imatinib cohort (75% vs. 31.8%, p = 0.021), the severity was milder. Conclusions: Imatinib showed longer disease control than the brachyury vaccine, though overall survival was similar. Future studies and deeper molecular insights are essential to develop better therapies and improve patient quality of life.

18 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHarshvardhan Iyer
Harshvardhan Iyer
JSJesus E. Sanchez-Garavito
Jesus E. Sanchez-Garavito
JZJorge Rios Zermeno
Jorge Rios Zermeno
ARAndrew Roberts
Andrew Roberts
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
KAKingsley O. Abode-Iyamah
Kingsley O. Abode-Iyamah
Background/Objectives: Postoperative opioid exposure after lumbar fusion remains a key clinical concern. Understanding which perioperative factors are associated with lower postoperative opioid use may help optimize recovery after minimally invasive (MIS) transforaminal lumbar interbody fusion (TLIF). This study aimed to determine if patients undergoing MIS-TLIF under spinal anesthesia (SA) showed lower postoperative opioid use compared to those undergoing MIS-TLIF under general anesthesia (GA). Methods: We retrospectively studied all adult patients (>18 years) undergoing 1- and contiguous 2-level MIS-TLIFs performed by a single surgeon. Patients undergoing the procedure under GA were compared to those undergoing the procedure under SA. Postoperative oral opioid use, up to 3 months post discharge, was collected. A 1:1 propensity score matching (PSM) protocol was implemented. Each outcome variable was initially assessed using univariate regression. Predictor variables with a p-value < 0.2 were included in the multivariate regression model. This was a retrospective, non-randomized study, and residual confounding cannot be excluded despite PSM. Results: The matched groups (n = 50 in each group) did not differ significantly depending on demographics or levels fused. Before regression, mean number of postoperative opioid prescriptions (p = 0.03), mean total operating room (OR) time in minutes (p < 0.01), and median length of stay (LOS) in days (p = 0.03) were significantly different. Multivariate regression showed that the GA group received 216.5 more total morphine milligram equivalents than the SA group (95% CI = 0.7–432.2, p = 0.049). The days of opioid use were higher in the GA group by 3.8 days (95% CI = 0.5 to 7.1, p = 0.025). On multivariate regression, LOS in hours was greater in the GA group by 14.1 h (p = 0.042). Conclusions: SA is an effective anesthetic modality for spinal surgery with the advantages of reduced postoperative opioid use, reduced OR time, and shorter LOS compared to GA.